Toronto, Ontario--(Newsfile Corp. - September 8, 2018) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or
the "Company"), a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and
management software solutions, announced that it is seeking approval from the TSX Venture Exchange to extend the expiry dates of
outstanding warrants exercisable to purchase an aggregate of 8,346,000 common shares of the Company at $0.075 per share. 7,300,000
of the warrants were issued by the Company on December 23, 2016 by way of a private placement and currently have an expiry date of
December 23, 2018. The Company is seeking to extend the expiry date of these warrants until December 23, 2020. 1,046,000 of the
warrants were issued by the Company on February 3, 2017 by way of a private placement and have an an expiry date of February 3,
2019. The Company is seeking to extend the expiry date of these warrants until February 3, 2021. All other terms and conditions of
the warrants remain unchanged.
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the
Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing
electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an
external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification,
is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial
condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm
Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on
information currently available to management. By their nature, forward-looking statements and forward-looking information involve
risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many
factors that could cause actual results and developments to differ materially from those expressed or implied by these
forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking
information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information
contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
